A current perspective on stereotactic body radiation therapy for pancreatic cancer.

Thumbnail Image



Journal Title

Journal ISSN

Volume Title

Repository Usage Stats


Citation Stats


Pancreatic cancer is a formidable malignancy with poor outcomes. The majority of patients are unable to undergo resection, which remains the only potentially curative treatment option. The management of locally advanced (unresectable) pancreatic cancer is controversial; however, treatment with either chemotherapy or chemoradiation is associated with high rates of local tumor progression and metastases development, resulting in low survival rates. An emerging local modality is stereotactic body radiation therapy (SBRT), which uses image-guided, conformal, high-dose radiation. SBRT has demonstrated promising local control rates and resultant quality of life with acceptable rates of toxicity. Over the past decade, increasing clinical experience and data have supported SBRT as a local treatment modality. Nevertheless, additional research is required to further evaluate the role of SBRT and improve upon the persistently poor outcomes associated with pancreatic cancer. This review discusses the existing clinical experience and technical implementation of SBRT for pancreatic cancer and highlights the directions for ongoing and future studies.





Published Version (Please cite this version)


Publication Info

Hong, Julian C, Brian G Czito, Christopher G Willett and Manisha Palta (2016). A current perspective on stereotactic body radiation therapy for pancreatic cancer. Onco Targets Ther, 9. pp. 6733–6739. 10.2147/OTT.S99826 Retrieved from https://hdl.handle.net/10161/13277.

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.



Brian Gary Czito

Professor of Radiation Oncology

Listed in Best Doctors in America. Listed in Top Doctors in North Carolina. His research interests include gastrointestinal malignancies, including treatment and integration of novel systemic agents with radiation therapy in the treatment of esophageal, gastric, hepatobiliary, pancreatic, colorectal and anal malignancies; phase I/II clinical trials evaluating novel systemic/targeted agents in conjunction with radiation therapy; investigation and optimization of the treatment of gastrointestinal malignancies, with focus on the above tumor sites.


Christopher G. Willett

Chair, Department of Radiation Oncology

Manisha Palta

Associate Professor of Radiation Oncology

Clinical research in gastrointestinal malignancies, lymphomas and breast malignancies.

Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.